UnitedHealthcare adopts limited coverage policy for Aduhelm Bancel has 'never been as busy' amid M&A talks as Moderna preps for life after COVID Amarin, after 33% revenue decline, aims to 'stabilize' US sales and grow in Europe FDA clears Abbott test to spot four STIs at once amid soaring case rates All Takeda wants for its billion-dollar gene therapy spending spree is functional cures IllumiCare launches EHR tool to automate clinical trial referral at point of care Fresenius Medical Care taps former Philips exec to take the reins after CEO's retirement Regeneron counts on Eylea's track record to fend off Roche rival Vabysmo FDA approves Orthofix's ultrasonic bone fracture healing system Biogen shoves Aduhelm to the side. It's time for lecanemab Siemens nearly doubles diagnostics forecast for the year amid renewed COVID testing surge Highmark Ventures, GuideWell back Healthmap's $35M round to scale up kidney care Featured Story | By Paige Minemyer The health insurance giant's coverage policy aligns with Medicare's recent coverage determination, with the insurer saying it will cover the drug for people in clinical trials and will require prior authorization. read more |
| |
|---|
|
|
| Power your data-science drug discovery Introducing the QIAGEN Biomedical Knowledge Base. The first expertly curated knowledge base that comes from high-quality manually curated content with granularity and causality that spans multiple domains. Learn more. |
Top Stories By Max Bayer Moderna CEO Stéphane Bancel said he's "never been as busy" as the company considers M&As to expand its business. read more By Zoey Becker After Amarin lost U.S. patent protections for its sole drug Vascepa, the company embarked on cost cuts and shifted to a digital-first marketing strategy. Now, the company aims to "stabilize" U.S. sales and grow its presence in Europe, execs said Wednesday. read more By Andrea Park The test was cleared by the FDA for samples collected in a healthcare setting, but Abbott also aims to bring STI screening into the home. read more By Annalee Armstrong Madhu Natarajan, head of Takeda’s Rare Disease Drug Discovery unit, knows that to many, cure is a “four-letter word.” But that's no reason not to try. read more By Anastassia Gliadkovskaya The app, which claims to be the first of its kind, suggests to providers in real-time if a patient meets the referral criteria for a clinical trial. read more By Andrea Park The year is still young, but Fresenius Medical Care is already looking ahead to 2023. read more By Kevin Dunleavy As Regeneron's Eylea tries to fend of competition from Roche's longer-acting Vabysmo, the company will rely on the track record of its blockbuster which raked in $9.2 billion in revenue last year. Regeneron’s answer is its own high-dose version—now in phase 3 testing—could reach the market in late 2023. read more By Conor Hale The AccelStim system is a nonsurgical treatment designed to be worn for 20 minutes per day for fresh bone breaks as well as fractures that have not healed on their own. read more By Annalee Armstrong Biogen’s CEO is out. Aduhelm is, essentially, on its last legs. So what’s in? Lecanemab, the monoclonal antibody the pharma hopes can reset some of the mistakes of the past. read more By Andrea Park As the majority of its testmaking peers significantly scaled back their predicted earnings from COVID-19 diagnostics for the rest of the year, Siemens Healthineers is moving in the complete opposite direction. read more By Heather Landi Two major Blues plans—GuideWell and Highmark Ventures—are backing kidney population health management company Healthmap Solutions. The company plans to fund R&D initiatives that provide innovative solutions to improve chronic kidney disease. read more |
